OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Pharmacology is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction	115
Corrigendum to “From “contraindicated” to “first line” – Current mechanistic insights beyond canonical β-receptor signaling” [COPHAR 76 (2024) 102458]	109
Editorial Board	96
Native botulinum toxin type A vs. redesigned botulinum toxins in pain: What did we learn so far?	80
From “contraindicated” to “first line” – Current mechanistic insights beyond canonical β-receptor signaling	68
Lipid raft disruption as an opportunity for peripheral analgesia	52
The role of extracellular ATP in homeostatic immune cell migration	52
The P2X7 purinoceptor in pathogenesis and treatment of dystrophino- and sarcoglycanopathies	47
Recent advances in emerging PCOS therapies	45
Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma	41
Optofluidic neural interfaces for in vivo photopharmacology	40
Editorial Board	38
Photo-isomerizable tweezers to probe ionotropic receptor mechanisms	38
Gastrointestinal issue: Advances in gastrointestinal oncology	36
Optic nerve regeneration: Potential treatment approaches	34
CRISPR-Cas9 in acute myeloid leukaemia: current state-of-art and future perspectives	34
Pancreatic alpha cells and glucagon secretion: Novel functions and targets in glucose homeostasis	33
Editorial overview: Special issue on “Rheumatology: Therapeutic advances for autoimmune and musculoskeletal diseases”	32
Advanced microneedle arrays for transdermal antibiotic delivery	31
Pharmaceutical therapies targeting autophagy for the treatment of age-related macular degeneration	31
Editorial Board	31
Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance	28
Three-dimensional culture models to study glioblastoma — current trends and future perspectives	28
Dyslipidemia and diabetes mellitus: Role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus	28
Current state of CFTR modulators for treatment of Cystic Fibrosis	27

Allogeneic double-negative T-cell therapy for acute myeloid leukemia	27
Paeoniflorin is a promising natural monomer for neurodegenerative diseases via modulation of Ca2+ and ROS homeostasis	27
Editorial Board	26
Animal models of cystic fibrosis in the era of highly effective modulator therapies	25
Therapeutic approaches in different congenital myopathies	25
Editorial Board	25
Gene therapies for RyR1-related myopathies	24
Strategies to enhance anti-leukaemia immunotherapy	23
Targeting TRP channels for pain relief: A review of current evidence from bench to bedside	23
Oligonucleotide-based therapies for cystic fibrosis	22
Antihypertensive effect of soybean bioactive peptides: A review	22
Lipids and lipid regulators in intraocular pressure homeostasis	22
Oncohistone-sculpted epigenetic mechanisms in pediatric brain cancer	22
Next-gen therapeutics to spare and expand beta-cell mass	21
Editorial overview: An initiative toward Ebolavirus disease (EVD) free world: An edited special anti-infective issue on Ebola virus disease	21
Smart solutions for tough infections: The rise of next-gen transdermal drug delivery	20
Shaping DNA damage responses: Therapeutic potential of targeting telomeric proteins and DNA repair factors in cancer	20
Photopharmacological approaches for dissecting potassium channel physiology	20
Non-alcoholic fatty liver disease: Current therapeutic options	20
Drug development for the treatment of RyR1-related skeletal muscle diseases	20
Nutraceuticals in mental diseases — Bridging the gap between traditional use and modern pharmacology	19
Photopharmacological control of cell signaling with photoswitchable lipids	19
Highlighting vulnerabilities in the alternative lengthening of telomeres pathway	19
Estrogen related receptor alpha: Potential modulator of age-related macular degeneration	19
Challenges in formulating transdermal systems for treating chronic skin infections	19
Editorial overview: “Purinergic immune cell regulation reveals novel pharmacological targets”	19
Purinergic signalling in graft-versus-host disease	18
Role of HSV-1 in Alzheimer's disease pathogenesis: A challenge for novel preventive/therapeutic strategies	18
Antibiotics, the microbiome and gastrointestinal cancers: A causal interference?	18
Light-activated receptor tyrosine kinases: Designs and applications	17
Functional role of the ER stress transducer IRE1α in CF airway epithelial inflammation	17
Targeting the NRF2 pathway: A promising approach for corneal endothelial dysfunction	17
Targeting fibroblast-like synoviocytes in rheumatoid arthritis	17
Editorial overview: COVID-19 therapy: From lung disease to systemic disorder	17
Advances in tethered photopharmacology for precise optical control of signaling proteins	16
NMR applications to GPCR recognition by peptide ligands	16
The expanding role of split protein complementation in opsin-free optogenetics	16
AI-driven GPCR analysis, engineering, and targeting	16
Pharmacoutilization data-driven artificial intelligence–assisted diagnosis algorithm to improve the pharmacological treatment of pain and agitation in patients suffering from severe dementia	16
Editorial Board	16
Novel approaches to CAR T cell target identification in acute myeloid leukemia	16
Editorial overview: Introduction to the musculoskeletal section of current opinion in pharmacology	15
Spinal and bulbar muscular atrophy: From molecular pathogenesis to pharmacological intervention targeting skeletal muscle	15
CFTR RNA- and DNA-based therapies	15
Fluorescent chemigenetic actuators and indicators for use in living animals	15
Novel treatments for dry eye syndrome	15
Targeting the endocannabinoid system for the management of low back pain	15